RE: CLX001 value25 Jun 2025 11:19
What percentage of new drugs fail?
Despite more than $130 billion in collective spending on pharmaceutical R&D, more than 90% of all new drugs fail during clinical trials. This means that for approximately every 5000 – 10 000 drug compounds, about one achieves US Food and Drug Administration (FDA) approval.
What is the success rate from research to market?
The drug research and development process include creating a drug, conducting preclinical and clinical studies, and receiving marketing approval after its regulatory review. This process is associated with an extremely low success rate, ~ 1 in 20,000–30,000.
CLX001 is not even close to being staged in preclinical trials , probably three or four more funding cycles away IMO and then any deal can only really be milestone led due to the vast costs to fund phase 1 human trials. This is why Big biotechs are incredidbly selective with an extensive DD process and only run with a very small number.
Varying Percentages:
The proportion of upfront payments within the total deal value can vary considerably. It may be influenced by factors like the specific drug, the stage of development, and the negotiating power of the parties involved.
Recent Trends:
A recent report indicates that upfront payments as a percentage of overall deal value have been declining. For example, in the first half of 2024, upfront payments accounted for only 6%.
It is more likely in 94% of cases that even if sucessful a deal would NOT include any upfront payment. Sorry @PM2022 but the VAL business here over the last 15 years has not proven that the business model actually works. The chances of a big chunk of cash landing short term to stave off the placing i would say is absolute ZERO chance. Hence why you are in full pump mode.